# Dasatinib in Treating Patients With Unresectable or Metastatic Squamous Cell Skin Cancer or RAI Stage 0-I Chronic Lymphocytic Leukemia

> **NCT00563290** · PHASE2 · COMPLETED · sponsor: **National Cancer Institute (NCI)** · enrollment: 7 (actual)

## Conditions studied

- Recurrent Skin Cancer
- Squamous Cell Carcinoma of the Skin
- Stage 0 Chronic Lymphocytic Leukemia
- Stage I Chronic Lymphocytic Leukemia

## Interventions

- **DRUG:** dasatinib
- **OTHER:** laboratory biomarker analysis

## Key facts

- **NCT ID:** NCT00563290
- **Lead sponsor:** National Cancer Institute (NCI)
- **Sponsor class:** NIH
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2007-11
- **Primary completion:** 2012-04
- **Final completion:** 2014-10
- **Target enrollment:** 7 (ACTUAL)
- **Last updated:** 2015-06-18


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00563290

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00563290, "Dasatinib in Treating Patients With Unresectable or Metastatic Squamous Cell Skin Cancer or RAI Stage 0-I Chronic Lymphocytic Leukemia". Retrieved via AI Analytics 2026-06-08 from https://api.ai-analytics.org/clinical/NCT00563290. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*